These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35792019)

  • 1. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Meyer HJ; Strobel A; Wienke A; Surov A
    Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
    Meyer HJ; Wienke A; Surov A
    Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
    Meyer HJ; Wienke A; Zamsheva M; Surov A
    Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
    March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
    Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
    Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
    Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
    HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Nutrition; 2021; 91-92():111417. PubMed ID: 34399402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography-defined body composition as prognostic markers for unfavourable outcomes and in-hospital mortality in coronavirus disease 2019.
    Meyer HJ; Wienke A; Surov A
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):159-168. PubMed ID: 35018725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis.
    Rinninella E; Cintoni M; Raoul P; Pozzo C; Strippoli A; Bria E; Tortora G; Gasbarrini A; Mele MC
    Clin Nutr; 2020 Jul; 39(7):2045-2054. PubMed ID: 31718876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
    Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
    Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis.
    Thormann M; Omari J; Pech M; Damm R; Croner R; Perrakis A; Strobel A; Wienke A; Surov A
    Langenbecks Arch Surg; 2022 Jun; 407(4):1369-1379. PubMed ID: 35583832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis.
    Surov A; Pech M; Gessner D; Mikusko M; Fischer T; Alter M; Wienke A
    Clin Nutr; 2021 Oct; 40(10):5298-5310. PubMed ID: 34536638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.
    Anabtawi NM; Pasala MS; Grimshaw AA; Kharel P; Bal S; Godby K; Siwakoti A; Buford TW; Bhatia S; Costa LJ; Williams GR; Giri S
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1084-1093. PubMed ID: 38558541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.
    Surov A; Strobel A; Borggrefe J; Wienke A
    Eur Radiol; 2023 Sep; 33(9):6426-6437. PubMed ID: 36929392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.
    Huiskamp LFJ; Chargi N; Devriese LA; May AM; Huitema ADR; de Bree R
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
    Surov A; Meyer HJ; Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Saalfeld S; Wienke A; Strobel A; Wolleschak D
    Eur Radiol; 2024 Feb; 34(2):790-796. PubMed ID: 37178198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model.
    Thormann M; Heitmann F; Wrobel V; Heinze C; March C; Hass P; Damm R; Surov A; Pech M; Omari J
    Dig Dis; 2023; 41(6):957-966. PubMed ID: 37385234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.